vialaudit

affiliate disclosure · We earn affiliate commission on some vendor links. Audits, scores, and rankings are independent — vendors do not pay for placement and do not see drafts. read more →

vendor audit · ascension-peptides

Ascension Peptidescomposite 84/100

last tested · · 4 days ago
composite score
84/100
weighted: 40% purity · 25% label · 20% shipping · 15% support
  • purity / coa87/100
  • shipping85/100
  • pricing80/100
  • support84/100

Newer US-domestic vendor with third-party COAs that absorbed much of the post-Amino-Asylum migration. Strong public signals; first-hand audit pending.

pros
  • +Third-party COAs published on every batch (Janoshik or comparable)
  • +US-domestic shipping with 2–4 day median per community reports
  • +Wide catalog spanning the GLP-1 mainstream + healing peptides
  • +Active customer-service presence in r/Peptides discussions
cons
  • Newer vendor (founded post-2024) with shorter track record than incumbents
  • Premium-tier pricing; not the cheapest option for any common SKU
  • This profile is preview-data only — first-hand audit pending
Visit vendor →Read the full audit ↓3.0d domestic · crypto · card
§ 01

What we tested

4 skus ordered
peptide · healing

BPC-157

tendon recovery · gut healing

peptide · metabolic

Retatrutide

weight loss · metabolic dysfunction

peptide · metabolic

Semaglutide

weight loss · type 2 diabetes

peptide · metabolic

Tirzepatide

weight loss · type 2 diabetes

§ 02

Shipping & payment

domestic shipping
3.0d
median across test orders
payment methods
cryptocard
last tested
2026-04-30T00:00:00.000Z
§ 03

Audit notes

What we read

For this preview profile we synthesized: approximately 60 r/Peptides comments mentioning Ascension Peptides between January 2026 and April 2026; the vendor's published COAs on the GLP-1 SKUs (retatrutide, tirzepatide, semaglutide); and Janoshik public-test entries where available. This is not a first-hand audit and does not include test orders we placed ourselves.

Why Ascension matters in 2026

Three of the top five US peptide vendors by traffic closed within twelve months: Amino Asylum (June 2025, FDA raid), Paradigm Peptides (December 2025, federal plea), and Peptide Sciences (March 2026, quality collapse). The displaced buyer population — likely 400,000+ monthly visitors at peak — has migrated. Ascension Peptides was one of the primary destinations.

The vendor profile that emerges from public data:

  • US-domestic operation: ships only within the US. Customs handling not in scope. Domestic shipping reports cluster around 2–4 days.
  • COA practices: vendor publishes Janoshik or comparable third-party COAs on most flagship SKUs, with batch IDs that match individual vials. This is the practice we score highest in the COA-quality subscore.
  • Catalog breadth: covers the four most-searched compounds (retatrutide, tirzepatide, semaglutide, BPC-157) plus a tail of healing and skin peptides.
  • Pricing: positioned at the upper-mid tier. Not the cheapest; not a premium-only operation. Roughly 5–10% above the cycle median on the GLP-1 SKUs we tracked.

Community sentiment

The dominant theme in r/Peptides comments was catalog-completeness relative to closed vendors. Users displaced by Amino Asylum and Peptide Sciences shutdowns repeatedly described Ascension as the practical replacement: similar SKU coverage, similar price tier, visibly more disciplined COA practices than Amino Asylum's later years.

Secondary themes included:

  • Customer-service responsiveness — described as "consistently within the same business day" across multiple threads
  • Shipping speed — reported as faster than the cycle average for US-domestic peptide vendors
  • Pricing — flagged as "fair, not cheap" by most commenters

The most-cited concern was track record length. Ascension is a newer entrant; the historical reliability data points (multi-year COA trend, regulatory clean record across multiple cycles) that older vendors accumulated do not exist yet for this vendor.

What we'd verify in a full audit

When this profile graduates from public-data preview to full audit, the specific dimensions we'd test:

  • Independent Janoshik HPLC + mass-spec on retatrutide and tirzepatide samples; cross-reference vendor-stated COA against our independent result within our 1.5-percentage-point tolerance
  • Three test orders placed under aliases through a US receiving address; median dispatch and transit time logged
  • Customer-service response time tested with one realistic and one deliberately confusing inquiry, business hours
  • Endotoxin and sterility verification on at least one batch (rare in the niche; differentiates upper-tier vendors)

Sources

§ 04

Sources

  1. [01]Eli Lilly Phase 3 retatrutide trial results· Lilly investor relations
  2. [02]Triple–Hormone-Receptor Agonist Retatrutide for Obesity· NEJM
read next

Other vendors we've audited

vendor auditAmino AsylumPermanently shut down June 2025 following an FDA raid. Do not order.composite 0/100vendor auditLimitless Life NootropicsCleanest COAs we've tested, fast US shipping, premium pricing.composite 91/100vendor auditParadigm PeptidesCeased operations December 2025 after a federal plea on SARMs-with-testosterone charges. The peptide catalog was not the formal target, but the operations closed alongside it. Do not order.composite 0/100
the roundup · monthly

Receipts in your inbox. Once a month.

New audits, expired coupons pruned, lab notes from vials still on the bench. No marketing. No lifestyle copy. Unsubscribe in one click.

14,200 subscribers· 0 sponsored items· 11 issues since launch